Süss A, Colsman A, Simon J C, Sticherling M
Klinik und Poliklinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Leipzig, Leipzig.
Hautarzt. 2009 Jan;60(1):51-6. doi: 10.1007/s00105-008-1571-6.
The availability of biologics for the therapy of psoriasis has radically changed the options for systemic therapy of this disease. Their use is often coupled with a variety of restrictions--as a rule they are to be used as a 'last-line' therapy. The status of previous systemic therapy as a basic requirement for the use of biologics is analyzed and simultaneously, the possibilities of the physician to use the indication spectrum of biologics for the benefit of the patient are demonstrated by case reports.
用于治疗银屑病的生物制剂的出现,彻底改变了这种疾病的全身治疗选择。它们的使用通常伴随着各种限制——通常它们被用作“一线”治疗。分析了先前全身治疗作为使用生物制剂的基本要求的状况,同时通过病例报告展示了医生利用生物制剂适应症范围为患者谋福利的可能性。